WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

A 5-month sprint: Behind Pfizer’s $10B deal and Innovent’s global pharma ambition

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s onc | Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five months to forge, but not without undergoing some stress tests.

Raccontata dafiercebiotech.comglobal.chinadaily.com.cnfiercepharma.com

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
fiercebiotech.comStai leggendo2 g fa

A 5-month sprint: Behind Pfizer’s $10B deal and Innovent’s global pharma ambition

Pfizer allocates $10.5B to Innovent Biologics via a five-month multi-asset deal for 12 oncology drugs. Validates Chinese biotech innovation and marks biopharma's turn toward bundled partnerships as standard M&A strategy over single-program hunting.

originale
global.chinadaily.com.cn2 g fa

Innovent-Pfizer deal makes joint development, commercialization pillar in biotech global push

The $10.5 billion partnership announced by Chinese innovative biotech Innovent Biologics and US pharmaceutical giant Pfizer in late May highlights an emerging shift in cross-border biotech dealmaking, with some Chinese…

Timeline cronologica

  1. lunedì 22 giugno 2026·fiercebiotech.com

    A 5-month sprint: Behind Pfizer’s $10B deal and Innovent’s global pharma ambition

    Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s onc | Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics…

  2. martedì 23 giugno 2026·global.chinadaily.com.cn

    Innovent-Pfizer deal makes joint development, commercialization pillar in biotech global push

    The $10.5 billion partnership announced by Chinese innovative biotech Innovent Biologics and US pharmaceutical giant Pfizer in late May highlights an emerging shift in…

Leggi questa versione →
originale
fiercepharma.com1 g fa

Big obesity bets and China's rise fuel potential $2T in 2032 drug sales: Evaluate

While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and more continue to dog the industry, even as pipelines bring massive s | While dealmaking…

Leggi questa versione → originale
  • martedì 23 giugno 2026·fiercepharma.com

    Big obesity bets and China's rise fuel potential $2T in 2032 drug sales: Evaluate

    While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and more continue to dog the industry, even as…

  • mercoledì 24 giugno 2026·fiercepharma.com

    Pfizer scores 1st expansion in 7 years for breast cancer blockbuster Ibrance

    It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug has started to lag sales of two others in its…